Literature DB >> 10369755

Polyanionic inhibitors of phosphoglycerate mutase: combined structural and biochemical analysis.

D J Rigden1, R A Walter, S E Phillips, L A Fothergill-Gilmore.   

Abstract

The effects that the inhibitors inositol hexakisphosphate and benzene tri-, tetra- and hexacarboxylates have on the phosphoglycerate mutases from Saccharomyces cerevisiae and Schizosaccharomyces pombe have been determined. Their Kivalues have been calculated, and the ability of the inhibitors to protect the enzymes against limited proteolysis investigated. These biochemical data have been placed in a structural context by the solution of the crystal structures of S. cerevisiae phosphoglycerate mutase soaked with inositol hexakisphosphate or benzene hexacarboxylate. These large polyanionic compounds bind to the enzyme so as to block the entrance to the active-site cleft. They form multiple interactions with the enzyme, consistent with their low Kivalues, and afford good protection against limited proteolysis of the C-terminal region by thermolysin. The inositol compound is more efficacious because of its greater number of negative charges. The S. pombe phosphoglycerate mutase that is inherently lacking a comparable C-terminal region has higher Kivalues for the compounds tested. Moreover, the S. pombe enzyme is less sensititive to proteolysis, and the presence or absence of the inhibitor molecules has little effect on susceptibility to proteolysis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369755     DOI: 10.1006/jmbi.1999.2848

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

1.  Unliganded structure of human bisphosphoglycerate mutase reveals side-chain movements induced by ligand binding.

Authors:  A Patterson; N C Price; J Nairn
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-10-27

2.  Inositol polyphosphates intersect with signaling and metabolic networks via two distinct mechanisms.

Authors:  Mingxuan Wu; Lucy S Chong; David H Perlman; Adam C Resnick; Dorothea Fiedler
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-19       Impact factor: 11.205

Review 3.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

Review 4.  Glucose metabolic phenotype of pancreatic cancer.

Authors:  Anthony K C Chan; Jason I E Bruce; Ajith K Siriwardena
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

5.  Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator).

Authors:  Hua Li; Gerwald Jogl
Journal:  J Biol Chem       Date:  2008-11-17       Impact factor: 5.157

6.  Rapid comparison of protein binding site surfaces with property encoded shape distributions.

Authors:  Sourav Das; Arshad Kokardekar; Curt M Breneman
Journal:  J Chem Inf Model       Date:  2009-12       Impact factor: 4.956

7.  Domain-based small molecule binding site annotation.

Authors:  Kevin A Snyder; Howard J Feldman; Michel Dumontier; John J Salama; Christopher W V Hogue
Journal:  BMC Bioinformatics       Date:  2006-03-17       Impact factor: 3.169

Review 8.  Phosphoglycerate Mutase 1: Its Glycolytic and Non-Glycolytic Roles in Tumor Malignant Behaviors and Potential Therapeutic Significance.

Authors:  Na Li; Xinlu Liu
Journal:  Onco Targets Ther       Date:  2020-02-27       Impact factor: 4.147

9.  CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii.

Authors:  Joseph D Lykins; Ekaterina V Filippova; Andrei S Halavaty; George Minasov; Ying Zhou; Ievgeniia Dubrovska; Kristin J Flores; Ludmilla A Shuvalova; Jiapeng Ruan; Kamal El Bissati; Sarah Dovgin; Craig W Roberts; Stuart Woods; Jon D Moulton; Hong Moulton; Martin J McPhillie; Stephen P Muench; Colin W G Fishwick; Elisabetta Sabini; Dhanasekaran Shanmugam; David S Roos; Rima McLeod; Wayne F Anderson; Huân M Ngô
Journal:  Front Cell Infect Microbiol       Date:  2018-10-05       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.